Zobrazeno 1 - 10
of 273
pro vyhledávání: '"Giulio, Metro"'
Publikováno v:
Oncology and Therapy, Vol 12, Iss 2, Pp 207-215 (2024)
Abstract Management of stage II–III non-small cell lung cancer (NSCLC) has been dramatically revolutionized by studies testing the addition of immunotherapy (IO) to chemotherapy in the pre- or perioperative setting. That is because the integration
Externí odkaz:
https://doaj.org/article/5f80fb1c915f465a8178995dc1c04e04
Autor:
Giulio Metro, Eleonora Gariazzo, Silvia Costabile, Sara Baglivo, Fausto Roila, Francesca Colamartini, Barbara Palumbo, Pietro Chiarini, Stefania Gori, Antonio Conti, Luca Marcomigni, Guido Bellezza, Gianluigi Lunardi
Publikováno v:
Oncology and Therapy, Vol 12, Iss 1, Pp 163-171 (2023)
Abstract In this work, we report on a clinically significant response of meningeal carcinomatosis to repotrectinib in a woman with a heavily pretreated ROS1-rearranged non-small cell lung cancer (NSCLC) that harbored the concomitant solvent front G20
Externí odkaz:
https://doaj.org/article/3a4ed1b09b5d4c588436e9abe5843e1f
Autor:
Carmen Molica, Alessio Gili, Carlotta Nardelli, Tiziana Pierini, Silvia Arniani, Donatella Beacci, Elena Mavridou, Martina Mandarano, Rodolfo Corinaldesi, Giulio Metro, Paolo Gorello, Paolo Giovenali, Nunzia Cenci, Corrado Castrioto, Marco Lupattelli, Fausto Roila, Cristina Mecucci, Roberta La Starza
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-8 (2023)
Abstract Our work reports implementation of a useful genetic diagnosis for the clinical managment of patients with astrocytic tumors. We investigated 313 prospectively recruited diffuse astrocytic tumours by applying the cIMPACT-NOW Update 3 signatur
Externí odkaz:
https://doaj.org/article/7425f994b5bb49f7be71b7cf6ab6cf14
Publikováno v:
Drugs in Context, Vol 12, Pp 1-3 (2023)
This Editorial by De Giglio, Ricciuti and Metro introduces the series Treatment of advanced non-small-cell lung cancer: one size does not fit all: https://www.drugsincontext.com/special_issues/treatment-of-advanced-non-small-cell-lung-cancer-one-size
Externí odkaz:
https://doaj.org/article/dbfe31b6a9cd418ba52c81122f5bbcbd
Autor:
Biagio Ricciuti, Alessia Mira, Elisa Andrini, Pietro Scaparone, Sandra Vietti Michelina, Federica Pecci, Luca Cantini, Andrea De Giglio, Giuseppe Lamberti, Chiara Ambrogio, Giulio Metro
Publikováno v:
Drugs in Context, Vol 11, Pp 1-11 (2022)
Constitutive KRAS signalling drives tumorigenesis across several cancer types. In non-small-cell lung cancer (NSCLC) activating KRAS mutations occur in ~30% of cases, and the glycine to cysteine substitution at codon 12 (G12C) is the most common KRAS
Externí odkaz:
https://doaj.org/article/efd943eaa9a848c685b57be6b709cef3
Autor:
Giulio Metro, Eleonora Gariazzo, Silvia Costabile, Sara Baglivo, Fausto Roila, Francesca Colamartini, Barbara Palumbo, Pietro Chiarini, Stefania Gori, Antonio Conti, Luca Marcomigni, Guido Bellezza, Gianluigi Lunardi
Publikováno v:
Oncology and Therapy, Vol 12, Iss 1, Pp 173-174 (2024)
Externí odkaz:
https://doaj.org/article/721958e30de148fbbf729425efe8aa14
Publikováno v:
Drugs in Context, Vol 11, Pp 1-16 (2022)
Oncogene addiction in non-small-cell lung cancer (NSCLC) has profound diagnostic and therapeutic implications. ALK, ROS1 and NTRK rearrangements are found in about 2–7%, 1–2% and 0.2% of unselected NSCLC samples, respectively; however, their freq
Externí odkaz:
https://doaj.org/article/3c44dabb2ca14f6fb53f96a72a8b8a59
Autor:
Federica Pecci, Luca Cantini, Giulio Metro, Biagio Ricciuti, Giuseppe Lamberti, Ammad Ahmad Farooqi, Rossana Berardi
Publikováno v:
Drugs in Context, Vol 11, Pp 1-17 (2022)
The treatment of non-small-cell lung cancer (NSCLC) harbouring EGFR mutations has witnessed some major breakthroughs in the last years. On the one hand, the recent advent of the third-generation tyrosine kinase inhibitor (TKI) osimertinib has reshape
Externí odkaz:
https://doaj.org/article/8411d7405da243b6a6da454804ce39f3
Autor:
Giulio Metro, Andrea De Giglio, Biagio Ricciuti, Marco Siringo, Daniele Marinelli, Alain Gelibter, Federica Pecci, Rossana Berardi, Luca Cantini, Alessandro Di Federico, Elisa Andrini, Mirta Mosca, Giuseppe Lamberti, Marta Brambilla, Giannis Mountzios
Publikováno v:
Drugs in Context, Vol 11, Pp 1-10 (2022)
EGFR exon 20 insertion mutations (Ex20ins) and HER2 mutations characterize an oncogene-addicted subtype of non-small-cell lung cancer (NSCLC) typically associated with a never or light smoking history, female sex, and adenocarcinoma histology. Nevert
Externí odkaz:
https://doaj.org/article/7f25efcbc0634ca08522dde133c6dc91
Autor:
Elisa Andrini, Mirta Mosca, Linda Galvani, Francesca Sperandi, Biagio Ricciuti, Giulio Metro, Giuseppe Lamberti
Publikováno v:
Drugs in Context, Vol 11, Pp 1-12 (2022)
Targeted therapy has dramatically changed the history and outcomes of oncogene-addicted non-small-cell lung cancer (NSCLC). RET rearrangements are typically observed in about 1–2% of NSCLC, resulting in constitutive activation of downstream signall
Externí odkaz:
https://doaj.org/article/810b165b7adb43dc9e5707cb1f20d5dc